抗体药物偶联物
文献类型：期刊论文
| 作者 | 曹刚1; 黄祚刚1; 程杰飞1; 姜标1 |
| 刊名 | Prog. Chem.
 |
| 出版日期 | 2014 |
| 卷号 | 26期号:2-3页码:467-477 |
| 其他题名 | Antibody-Drug Conjugates |
| 通讯作者 | 程杰飞 ; 姜标 |
| 英文摘要 | Over 35 monoclonal antibody drugs have been marketed since the approval of first monoclonal antibody drug in 1986, making the antibody drug development one of the most exciting fields. Antibody-drug conjugate (ADC), which combines a monoclonal antibody (mAb) with a cytotoxic (drug) molecule through a linker and thereby the name, is a new class of highly potent biopharmaceutical drugs designed as a targeted therapy. ADC takes advantage of the high binding specificity of mAbs and superior efficacy of cytotoxic molecules, while avoiding the dose-limiting toxicity of cytotoxic molecules. The first ADC, Mylotarg, was approved in 2000, which was late withdrawn by the manufacture due to the lack of appropriate stability of the linker. So far, there are two approved ADCs in the market for cancer therapy and over twenty ADCs in various stages of clinical trials. Creating a successful antibody drug conjugate requires careful selection of the drug, antibody and linker. Linker has a great influence on a conjugate' s biological characteristics, such as stability in circulation and drug release at the target site. ADCs have been proven to be effective weapons against cancers and will certainly become useful therapeutics against other diseases. |
| 学科主题 | 天然产物有机化学 |
| 收录类别 | SCI |
| 原文出处 | http://dx.doi.org/10.7536/PC130650 |
| 语种 | 中文 |
| 源URL | [http://ir.sioc.ac.cn/handle/331003/38978]  |
| 专题 | 上海有机化学研究所_中科院天然产物有机化学重点实验室 |
| 作者单位 | 1.中科院上海高等研究院 2.大冢(上海)药物研究开发有限公司 3.中科院上海有机化学研究所 4.上海科技大学 |
| 推荐引用方式 GB/T 7714 | 曹刚,黄祚刚,程杰飞,等. 抗体药物偶联物[J]. Prog. Chem.,2014,26(2-3):467-477. |
| APA | 曹刚,黄祚刚,程杰飞,&姜标.(2014).抗体药物偶联物.Prog. Chem.,26(2-3),467-477. |
| MLA | 曹刚,et al."抗体药物偶联物".Prog. Chem. 26.2-3(2014):467-477. |
入库方式： OAI收割
来源：上海有机化学研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。